Stock CPMV MOSAIC IMMUNOENGINEERING, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Mosaic ImmunoEngineering, Inc.

Equities

CPMV

US61945M1018

Biotechnology & Medical Research

Market Closed - OTC Markets
Other stock markets
 02:18:57 2024-04-24 pm EDT 		5-day change 1st Jan Change
0.3131 USD +0.03% Intraday chart for Mosaic ImmunoEngineering, Inc. -22.11% -47.82%
Apr. 15 Mosaic ImmunoEngineering, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Mar. 28 Mosaic ImmunoEngineering, Inc. Receives Letter of Termination from CWRU CI

Valuation

Fiscal Period: December 2020 2021 2022 2023
Capitalization 1 2.619 7.373 7.17 4.345
Enterprise Value (EV) 1 2.618 7.882 8.177 5.507
P/E ratio -1.69 x -1.85 x -3 x -4.29 x
Yield - - - -
Capitalization / Revenue - - - -
EV / Revenue - - - -
EV / EBITDA - - - -
EV / FCF - 13,403,204 x 41,642,551 x -83,314,018 x
FCF Yield - 0% 0% -0%
Price to Book -6.2 x -2.64 x -1.47 x -0.74 x
Nbr of stocks (in thousands) 806 7,228 7,242 7,242
Reference price 2 3.250 1.020 0.9900 0.6000
Announcement Date 3/2/21 1/26/22 3/2/23 4/15/24
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2020 2021 2022 2023
Net sales - - - -
EBITDA - - - -
EBIT 1 -1.433 -3.501 -2.628 -1.4
Operating Margin - - - -
Earnings before Tax (EBT) 1 -1.441 -3.682 -2.378 -1.006
Net income 1 -1.444 -3.684 -2.381 -1.008
Net margin - - - -
EPS 2 -1.920 -0.5500 -0.3300 -0.1400
Free Cash Flow - 0.588 0.1964 -0.0661
FCF margin - - - -
FCF Conversion (EBITDA) - - - -
FCF Conversion (Net income) - - - -
Dividend per Share - - - -
Announcement Date 3/2/21 1/26/22 3/2/23 4/15/24
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2020 2021 2022 2023
Net Debt 1 - 0.51 1.01 1.16
Net Cash position 1 0 - - -
Leverage (Debt/EBITDA) - - - -
Free Cash Flow - 0.59 0.2 -0.07
ROE (net income / shareholders' equity) - 229% 62% 18.7%
ROA (Net income/ Total Assets) - -602% -619% -397%
Assets 1 - 0.6123 0.3848 0.254
Book Value Per Share 2 -0.5200 -0.3900 -0.6700 -0.8100
Cash Flow per Share 2 0.4400 0.0300 0.0300 0.0200
Capex - - - -
Capex / Sales - - - -
Announcement Date 3/2/21 1/26/22 3/2/23 4/15/24
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
MOSAIC IMMUNOENGINEERING, INC. Stock Mosaic ImmunoEngineering, Inc.
-47.82% 2.27M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. CPMV Stock
  4. Financials Mosaic ImmunoEngineering, Inc.